Prime Medicine
Gene editing

Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly “search and replace” to restore normal genetic function and address the fundamental causes of disease. Prime Medicine envisions a world where Prime Editing can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients and shaping the future of gene editing. The company is currently advancing multiple drug discovery programs targeted at liver, eye, ex-vivo hematopoietic stem cell, and neuro-muscular indications. Prime Editing was developed by scientific founders David R. Liu, PhD and Andrew Anzalone, MD, PhD, at the Broad Institute of MIT and Harvard.


University
Harvard University
Massachusetts Institute of Technology
The Broad Institute
Sector
Life Science
Status
Active
Initial Investment Stage
Early
Team
View Website